For many people diagnosed with focal segmental glomerulosclerosis (FSGS), the story starts the same way: “I didn’t feel anything at first.” “I thought it was something minor.” “I didn’t know until it was serious.”
That’s not a coincidence, it’s a pattern. FSGS is a kidney disease that can quietly progress for months or even years before it’s detected. And for Black patients in particular, diagnosis is often delayed, missed, or misunderstood altogether.
This isn’t just about biology. It’s about how symptoms present, how the healthcare system responds, and how disparities shape outcomes. Understanding why FSGS is often missed—and how to advocate for earlier intervention—can change the trajectory of care.
RELATED: Living With FSGS: 5 Daily Habits That Can Help Protect Your Kidneys
One of the biggest challenges with FSGS is that it doesn’t always announce itself clearly. In the early stages, symptoms can be subtle or easy to overlook:
Many people don’t experience noticeable symptoms until kidney damage has already progressed. In fact, kidney disease—including FSGS—can remain asymptomatic until later stages, when complications become more severe. That means diagnosis often depends on:
If those steps don’t happen early, the condition can quietly advance.
RELATED: Why Understanding Your FSGS Type Changes Matters
FSGS doesn’t affect all populations equally. Research shows that the condition is significantly more common in Black Americans, with incidence rates about four times higher than in white populations. And when it does occur, it often progresses more aggressively.
One major reason is genetics—specifically, variants in the APOL1 gene. These variants, which are more common in people of African ancestry, are strongly linked to increased risk of FSGS and other kidney diseases. In fact:
These genetic factors don’t guarantee disease, but they significantly increase vulnerability. At the same time, Black Americans develop kidney failure at nearly four times the rate of those of European ancestry. That combination—higher risk and faster progression—makes early detection even more critical.
Even when symptoms are present, FSGS is often misdiagnosed or overlooked. Why? Because its early signs can mimic more common conditions:
And in some cases, systemic bias plays a role. Black patients are more likely to have symptoms minimized or attributed to other causes, delaying appropriate testing and referral. FSGS also requires a kidney biopsy for definitive diagnosis, which isn’t always pursued early, especially if symptoms seem mild or unclear. The result is a dangerous gap:
It’s impossible to talk about delayed diagnosis without acknowledging the broader context. Black patients face higher rates of:
These systemic factors compound the biological risk. Even when someone seeks care, they may not receive:
And because FSGS can progress quickly, those delays matter. They can mean the difference between early intervention and advanced kidney disease.
FSGS is often identified through:
Protein in the urine—known as proteinuria—is one of the earliest and most important warning signs. But if that test isn’t done early, the opportunity for early detection can be missed. That’s why advocacy matters. Because in many cases, testing doesn’t happen unless it’s requested—or strongly considered.
If you’re at higher risk—whether due to family history, symptoms, or background—it’s important to be proactive.
A simple urine test can detect protein levels early. You can ask:
Blood tests can measure how well your kidneys are working. Ask:
Even mild symptoms matter. If you notice:
…bring it up clearly and directly.
If you’re of African ancestry, it’s reasonable to ask about APOL1-related risk. Genetic testing isn’t always routine—but it can provide important context for kidney disease risk.
Not every case requires immediate specialist care—but many do. You should consider asking for a nephrology referral if:
Nephrologists specialize in kidney disease and are more likely to:
Waiting too long to see a specialist can delay critical interventions.
Advocacy isn’t just about asking for tests. It’s about asking the right questions. Here are a few that can make a difference:
You don’t need to have all the answers. But asking questions opens the door to better care.
One of the most important shifts is moving away from: “I didn’t know until it was serious”
…to: “I caught it early.” That shift doesn’t happen by chance. It happens through:
And while not every case can be prevented or caught early, many can be identified sooner with the right approach. FSGS is often missed—not because it’s rare, but because it’s quiet. Symptoms can be subtle. Diagnosis requires specific testing. And for Black patients, risk is higher—but recognition is often delayed. That’s why early detection matters.
Because kidney disease doesn’t always start loudly. But catching it early can make all the difference.
By subscribing, you consent to receive emails from BlackDoctor.com. You may unsubscribe at any time. Privacy Policy & Terms of Service.
